1-(Phenylmethyl),(3R,4S)-4-Ethyl-1,3-Pyrrolidinecarboxylate

Production-scale hydrogenation of the benzyl-protected pyrrolidine ester under 0.35–0.42 MPa H₂ pressure in a Hastelloy C-22 stirred autoclave fitted with a gas-inducing impeller has revealed a reproducible exotherm onset at 38°C when 5% Pd/C (Type 87L, 1.8% w/w relative to substrate) is used in denatured ethanol at 12 volumes. Deviation beyond 42°C triggers a runaway N-debenzylation pathway that generates 3–7% of the ring-opened secondary amine impurity, quantified by GC-FID per USP 〈621〉 after trifluoroacetic anhydride derivatization. The liberated (3R,4S)-4-ethylpyrrolidine-3-carboxylic acid, isolated as its hydrochloride salt after solvent swap to 2-propanol and HCl gas sparging at −5°C, serves as the common C₂-symmetric backbone for a family of dipeptidyl peptidase inhibitors. In pilot-plant campaigns exceeding 80 kg input, batch-to-batch enantiomeric excess measured by chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm, hexane/ethanol/diethylamine 90:10:0.1) remained at ≥99.2% only when the crude ester was first recrystallized from methylcyclohexane/tetrahydrofuran (3:1) to an HPLC purity of ≥99.5 area% prior to hydrogenolysis; failure to meet this threshold caused a 1.2% mean ee erosion attributable to base-catalyzed epimerization at C3 during solvent stripping. The free acid intermediate is subsequently coupled to heterocyclic amines under classical EDCl/HOBt activation in dichloromethane, generating the penultimate amide that yields a marketed oral antihyperglycemic agent after salt formation with citric acid.

What Occurred When the Ester Was Evaluated as a Chiral Auxiliary in Rodent-Selective Thrombin Inhibitor Synthesis?

Incorporation of 1-(phenylmethyl),(3R,4S)-4-ethyl-1,3-pyrrolidinecarboxylate as a proline surrogate during solution-phase peptide coupling with N-Boc-trans-4-aminocyclohexanecarboxylic acid revealed a critical racemization risk at the acyl carbon when HATU was employed with N-methylmorpholine in dimethylformamide at 20°C; the undesired (3S,4R) diastereomer reached 4.8% within 45 minutes as determined by reverse-phase UPLC at 210 nm. Switching to PyBOP with 2,6-lutidine at 0–5°C suppressed epimerization to ≤0.3% and maintained a coupling yield of 87% after aqueous workup. The resultant intermediate, after TFA-mediated Boc removal and sulfonamide formation, provided a factor Xa-directed lead compound whose Ki against human α-thrombin necessitated the (3R,4S) absolute configuration to orient the pyrrolidine ethyl substituent into the hydrophobic S2 pocket. The process stream required rigorous control of residual DMF (≤ 0.05% by headspace GC–MS per ICH Q3C) because carryover into the final crystallization from ethyl acetate/n-heptane reduced the eutectic point, causing oiling-out and a 14% yield loss documented across three consecutive GMP batches in a 200 L glass-lined reactor. The terminal active pharmaceutical ingredient, obtained as a white crystalline besylate salt, conforms to ICH Q6A specifications for related substances with limits of ≤0.10% for any single impurity and ≤0.5% total impurities.

Chiral Pyrrolidine Scaffold in HCV NS3/4A Protease Inhibitor Process Chemistry

When the ethyl-substituted phenylmethyl ester was employed as a P2 proline mimetic for a macrocyclic hepatitis C protease inhibitor, the tertiary amine required chemoselective N-debenzylation in the presence of a vinylcyclopropane warhead without alkene hydrogenation. The accepted manufacturing route utilized α-chloroethyl chloroformate (ACE-Cl) in 1,2-dichloroethane at 55°C followed by methanolysis; however, over-chlorination at the pyrrolidine α-position generated a persistent 0.8% impurity that co-eluted with the product during silica gel chromatography. Implementation of a biphasic ACE-Cl cleavage with 3 M aqueous sodium acetate–methanol (1:1 v/v) at reflux suppressed this side product below 0.05% and allowed telescoping into the subsequent acylation with cyclopropanesulfonyl chloride. The addition level of the activated ester in the macrocyclization step was fixed at 1.08 equivalents relative to the linear tetrapeptide; excess beyond 1.12 mol·eq led to dimerization, confirmed by MALDI-TOF (m/z 1682.9) and requiring preparative SFC purification that consumed 9.4 kg CO₂ per kilogram of purified product. The final macrocycle, isolated as an amorphous sodium salt by spray drying, conforms to the ICH M7 guideline for mutagenic impurities, with the ACE-Cl-derived 2-chloroethyl carbamate purge factor verified at 4.2 × 10⁴ by spiking-and-clearance studies. Finished dosage forms include film-coated tablets containing 75 mg and 150 mg of the free acid equivalent, formulated with copovidone and sodium lauryl sulfate via hot-melt extrusion at 145°C barrel temperature.

The base-sensitive nature of the (3R,4S) diester becomes operationally decisive when telescoping into strongly alkaline peptide hydrolysis protocols. During kilogram-scale saponification with 2N aqueous lithium hydroxide in tetrahydrofuran at 0°C, the ethyl ester at position 4 remained unaffected, while the methyl ester at position 3 hydrolyzed within 1.5 hours to the corresponding acid. Extending the hydrolysis time to 3 hours resulted in 2.1% epimerization at C3, corroborated by ¹³C NMR resonances at 172.8 and 173.1 ppm for the two diastereomeric carboxyl carbons. The monoacid was subsequently coupled to 3-fluoro-4-(trifluoromethoxy)benzylamine using isobutyl chloroformate and N-methylmorpholine in acetonitrile, producing the penultimate amide with an in-process control threshold of NMT 0.8% for the des-fluoro impurity. Final hydrogenolysis with Pearlman’s catalyst in a 50 psig hydrogen atmosphere in ethanol/water (4:1) yielded a secondary amine that was directly crystallized as the di-p-toluoyl-L-tartrate salt, achieving 99.8% chemical purity and 99.6% diastereomeric excess. The active substance is classified under the JP Pharmacopoeia monographs and requires storage at −20°C ± 5°C in double LDPE bags inside HDPE drums.

Enantioselective Organocatalysis: When the Pyrrolidine Core Becomes a Bifunctional Thiourea Catalyst Precursor

Conversion of the N-benzyl-protected ester into a bifunctional thiourea organocatalyst commences with lithium aluminum hydride reduction of the ester to the primary alcohol in tetrahydrofuran at 0–5°C, followed by mesylation and nucleophilic displacement with sodium azide in dimethyl sulfoxide at 65°C for 16 hours. The intermediate azide is hydrogenated to the primary amine, which is immediately treated with 3,5-bis(trifluoromethyl)phenyl isothiocyanate in dichloromethane at 25°C to furnish the thiourea. In the enantioselective Michael addition of diethyl malonate to trans-β-nitrostyrene, 5 mol% catalyst loading in toluene at −20°C afforded the adduct in 93% yield and 96% ee, but the presence of residual sodium azide above 10 ppm (quantified by ion chromatography per ASTM D4327) poisoned the palladium catalyst during benzyl deprotection. A mandatory aqueous sodium nitrite quench followed by sulfamic acid treatment reduced azide content to ≤2 ppm. The catalyst’s tert-amine moiety requires protonation with benzoic acid (10 mol%) for optimal turnover, a condition that simultaneously risks retro-aldol cleavage if the reaction temperature rises above −15°C. During the scale-up of the nitroalkene conjugate addition in a jacketed 50 L glass reactor, a cooling failure lasting 8 minutes elevated the jacket outlet temperature to −8°C and decreased enantiomeric excess to 82%, demonstrating the processing window of ≤7°C deviation. The transformed chiral pyrrolidine-thiourea catalyst is a non-GMP research chemical, but its synthesis from the parent ester is conducted under ISO 9001:2015-certified quality management with full traceability to the lot of raw material used.

Phosphoramidite ligand construction from the same C₂-symmetric amino alcohol intermediate began with selective O-phosphitylation using 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and diisopropylethylamine in tetrahydrofuran. The resulting monodentate ligand, after column chromatography on neutral alumina (Brockmann activity III) to remove phosphite esters, facilitated rhodium-catalyzed asymmetric hydrogenation of methyl 2-acetamidoacrylate with 99.2% ee at 0.05 MPa H₂ and a substrate-to-catalyst ratio of 10,000. The phosphoramidite must be stored as a 0.5 M solution in degassed toluene under argon at −30°C; exposure to air for > 2 hours results in 22% oxidation to the phosphoramidate by ³¹P NMR (δ 8.2 ppm vs. δ 148.6 ppm). Ligand loading of 1.2 mol% relative to rhodium, combined with a preformation time of 30 minutes, established a turnover frequency of 1,800 h⁻¹, which declined to 420 h⁻¹ when the ligand was aged for 72 hours at −10°C. This specific degradation trajectory, documented via kinetic profiling in a Mettler-Toledo EasyMax reactor, defines the shelf-life specification of 6 weeks under the recommended storage condition and is a critical parameter for technology transfer to fine-chemical toll manufacturers operating under ISO 14001 environmental management.

In a parallel drug substance program targeting a selective κ-opioid receptor antagonist, the ethyl-substituted phenylmethyl ester was transformed into the corresponding Weinreb amide via direct aminolysis with N,O-dimethylhydroxylamine hydrochloride and isopropylmagnesium chloride in tetrahydrofuran at −15°C without prior ester hydrolysis. This unconventional route circumvented the epimerization-prone carboxylic acid intermediate and maintained the (3R,4S) configuration with 99.7% retention as confirmed by vibrational circular dichroism. The Weinreb amide was subsequently reacted with 4-bromophenylmagnesium bromide to yield the aryl ketone, a key intermediate for a dibenzylamine series intended for neuropathic pain. During the Grignard addition at −20°C, a single instance of moisture ingress through a faulty septum in a 500 mL Schlenk flask resulted in a 12% exotherm to −4°C and generation of the des-bromo protodehalogenated impurity at 4.7%, prompting a standard operating procedure mandating septum replacement after every 3 reactions and continuous Karl Fischer monitoring of the tetrahydrofuran feed (≤50 ppm H₂O). The final active pharmaceutical ingredient, a hydrochloride salt of the O-demethylated derivative, is subject to the requirements of 21 CFR Part 211 for current good manufacturing practice, with release testing per USP monographs including assay by potentiometric titration (98.0–102.0%) and chiral purity by capillary electrophoresis.

Peptidomimetic Design for Integrin αvβ3 Antagonists and the (3R,4S) Conformational Lock

Insertion of the 4-ethyl-3-aminopyrrolidine motif derived from the title ester into the RGD-mimetic pharmacophore of a cyclic pentapeptide was achieved by Fmoc solid-phase peptide synthesis on 2-chlorotrityl chloride resin (loading 0.8 mmol/g). The non-commercial amino acid building block, obtained by catalytic hydrogenolysis of the benzyl group followed by Fmoc protection of the secondary amine and saponification of the ester, was coupled using HBTU and 0.5 M DIPEA in DMF for 50 minutes. Acylation yields at the sterically hindered pyrrolidine nitrogen dropped to 62% when the preceding residue was N-methylphenylalanine, necessitating double coupling and a 2-fold increase in building block consumption. The linear peptide was cleaved from the resin with 20% HFIP in dichloromethane, preserving the tert-butyl protecting groups, and cyclization was performed with T3P and N-methylmorpholine at 2 mM concentration to suppress dimer formation to <5% by analytical SEC. After global deprotection with TFA/triisopropylsilane/water (95:2.5:2.5), the crude cyclic peptide exhibited an IC₅₀ of 0.8 nM for αvβ3 in a solid-phase binding assay, with a selectivity ratio of 1:240 against αIIbβ3. The process was transferred to a CMO facility where residual TFA in the final lyophilized product was controlled to ≤0.5% by ion chromatography (DIN 55609), using a lyophilization cycle with a primary drying shelf temperature of −30°C and secondary drying at 25°C for 9 hours at 0.2 mbar. This peptidomimetic candidate, administered as a lyophilized powder for reconstitution in phosphate-buffered saline, is classified as an investigational new drug, and the pyrrolidine starting material lot must be accompanied by a CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia) or equivalent ASMF documentation.

In a dedicated campaign for a purinergic P2Y₁₂ receptor antagonist backup series, the tartaric acid salt of the primary amine intermediate was resolved a second time via classical diastereomeric salt formation with (S)-mandelic acid in ethanol/water (9:1) to upgrade the enantiomeric purity from 99.1% to 99.95% ee, a necessity driven by the chiral discrimination requirements of the target protein’s allosteric pocket. The enhanced purity amine was then reductively alkylated with ethyl 4-oxocyclohexanecarboxylate using sodium triacetoxyborohydride in acetic acid/dichloromethane at −10°C, forming a tertiary amine with a cis-substituted cyclohexyl ester. Subsequent aminolysis with 2,2,2-trifluoroethylamine yielded an amide that was cyclized with phosphorus oxychloride to a tetrahydropyridine ring, the key intermediate for a platelet aggregation inhibitor. In a kilo-lab demonstration, the cyclohexane reductive amination suffered an unpredictable induction period of 18–22 minutes followed by a rapid exotherm of 12°C per minute when the substrate exceeded 0.35 M concentration, requiring a controlled addition protocol with reaction calorimetry feedback (Mettler Toledo RC1e, jacket setpoint −5°C). The final compound was formulated as an orally disintegrating tablet containing 10 mg of active blended with mannitol, crospovidone, and magnesium stearate, meeting USP 〈701〉 disintegration time of ≤30 seconds. Entire synthetic route validation was conducted under the auspices of ICH Q11, with the starting material designation of the (3R,4S) pyrrolidine ester justified via a synthetic scheme of three chemical transformation steps from commercially available raw materials.